Browse studies

Find your next paid study

8 recruiting studies matching your filters

Androgen Replacement to Improve Patient-Important Outcomes in Men With Opioid-Induced Hypogonadism

The aim of this trial is to evaluate whether testosterone replacement results in greater improvement in pain perception, pain tolerance, sexual function, fatig…

Opioid UsePainHypogonadism, Male

Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT04798469

Detection of Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Exposed to Cisplatin-based Chemotherapy and Bone Marrow Transplant

Late subclinical cardiovascular disease in testicular cancer survivors exposed to cisplatin-based chemotherapy and bone marrow transplant

Testicular CancerSurvivorshipASCVD+5 more

Estimated

~$10 – $750

Indiana UniversityNCT05611307

Phase 4

Safety of Intramuscular Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

The purpose of this study is evaluate the safety of testosterone replacement therapy in men with newly diagnosed low-risk prostate cancer and hypogonadism on a…

Prostate CancerHypogonadism, Male

Estimated

~$10 – $6,250

University of MiamiNCT07278362

Phase 2

Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer

The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug fo…

Hypogonadism, MaleFatigue Syndrome, Chronic

Estimated

~$10 – $6,250

Seattle Institute for Biomedical and Clinical ResearchNCT04049331

Phase 4

A Multi-center, Open-label, Single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Study of Testosterone Cypionate Injection in Hypogonadal Men

A Phase 4, multi-center, open-label, single-arm 24-hour Ambulatory Blood Pressure Monitoring (ABPM) study of Testosterone Cypionate Injection in Hypogonadal Me…

Hypogonadism, Male

Estimated

~$10 – $8,750

Azurity PharmaceuticalsNCT07328542

Phase 3

Open-Label, Multiple-Dose, 52-Week Study + 24-Month Long-Term Safety Extension to Evaluate the Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism

This is a 52-week open label single arm study + 24-Month long-term safety extension to investigate the effects of XYOSTED, as testosterone replacement therapy,…

Hypogonadism, Male

Estimated

~$10 – $8,750

Halozyme TherapeuticsNCT06689085

Observational

Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy

To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothel…

Erectile DysfunctionHypogonadism, MaleEndothelial Dysfunction

Estimated

~$10 – $6,250

University of California, IrvineNCT06720597

Phase 2

Effect of JATENZO® Therapy on Testosterone and Hemoglobin Concentrations in Hypogonadal Men With Chronic Kidney Disease

This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone …

Hypogonadism, MaleKidney Disease, Chronic

Estimated

~$10 – $6,250

St. Louis UniversityNCT05249634